Rating for VRNA
Verona Pharma plc - American Depositary Shares (VRNA)
US:NASDAQ Investor Relations:
nasdaq.com/symbol/vrna/real-time
Company Research
Source: Benzinga
Impact Snapshot
Event Time:
VRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRNA alerts
High impacting Verona Pharma plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
VRNA
News
- Verona Pharma plc (NASDAQ: VRNA) is now covered by analysts at Roth Mkm. They set a "buy" rating and a $68.00 price target on the stock.MarketBeat
- Orna Therapeutics Appoints Vikas Sinha to its Board of DirectorsPR Newswire
- Verona Pharma plc (NASDAQ: VRNA) had its price target raised by analysts at Wells Fargo & Company from $64.00 to $74.00. They now have an "overweight" rating on the stock.MarketBeat
- Verona Pharma plc (NASDAQ: VRNA) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $57.00 price target on the stock, up previously from $44.00.MarketBeat
- Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights [Yahoo! Finance]Yahoo! Finance
VRNA
Sec Filings
- 1/7/25 - Form 8-K
- 12/6/24 - Form 4
- 12/6/24 - Form 4
- VRNA's page on the SEC website